Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01474135 · ClinicalTrials.gov registry record · Phase 2
AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT01474135 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 93 participants.
The verdict
NCT01474135, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure
Interventions
- DRUG 0.25% AR-12286 / 0.004% travoprost
- DRUG 0.5% AR-12286, 0.004% travoprost
- DRUG 0.004% Travoprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2011-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01474135
The ClinicalTrials.gov registry entry for NCT01474135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aerie Pharmaceuticals, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 0.25% AR-12286 / 0.004% travoprost is the first listed.
NCT01474135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01474135 about?
NCT01474135 is a clinical study titled "AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure". This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular pressure
What is the current status of trial NCT01474135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2011-12. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01474135?
The interventions under investigation include: 0.25% AR-12286 / 0.004% travoprost (DRUG), 0.5% AR-12286, 0.004% travoprost (DRUG), 0.004% Travoprost (DRUG).
Who is sponsoring clinical trial NCT01474135?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.